Location History:
- Tenafly, NJ (US) (2003)
- Sparta, NJ (US) (2014 - 2016)
Company Filing History:
Years Active: 2003-2016
Title: Kapil Dhingra: Innovator in Combination Therapy for Proliferative Disorders
Introduction
Kapil Dhingra is a notable inventor based in Sparta, NJ (US). He has made significant contributions to the field of medicine, particularly in the area of combination therapies for treating proliferative disorders. With a total of 3 patents, his work focuses on innovative treatments for various types of solid tumors.
Latest Patents
Dhingra's latest patents include a groundbreaking combination therapy for proliferative disorders. The first patent relates to a combination therapy involving propane-1-sulfonic acid and interferon, specifically peginterferon alfa-2a, aimed at treating patients with solid tumors such as colorectal cancer, melanoma, and thyroid cancer. Notably, this therapy is designed for cases where the melanoma contains the V600E b-Raf mutation. The second patent also focuses on a combination therapy of propane-1-sulfonic acid, this time in conjunction with an EGFR inhibitor, targeting similar solid tumors.
Career Highlights
Throughout his career, Kapil Dhingra has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer treatment.
Collaborations
Dhingra has collaborated with notable professionals in his field, including Brian Higgins and Kenneth Kolinsky. These partnerships have contributed to the advancement of his research and the successful development of his patented therapies.
Conclusion
Kapil Dhingra's work in combination therapies represents a significant advancement in the treatment of proliferative disorders. His innovative patents and collaborations highlight his commitment to improving patient outcomes in oncology.